SpectRx has been granted a second patent in 60 days for its SimpleChoice patch insulin pump infusion set, with additional applications are pending.

“We are very pleased with the news of the additional patent, and continue to be greatly encouraged by comments from pump users who have evaluated the patch,” said Bill Arthur, president and COO of SpectRx. “The combination of proprietary technology and positive user feedback increasingly point to an important market opportunity for the company.”

The SimpleChoice patch is for use with insulin pumps worn by people with diabetes to control their insulin levels. The FDA-cleared patch is designed for use with most insulin pumps on the market today and delivers insulin through five microneedles

The annual U.S. insulin pump infusion set market is estimated to be approximately $270 million.

SpectRx: www.spectrx.com